Tazovex Indications/Uses

PIPERACILLIN AND TAZOBACTAM FOR INJECTION is indicated for the treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected: Lower respiratory tract infections, Urinary tract infections (complicated and uncomplicated), Intra-abdominal infections, Skin and skin structure infections, Bacterial septicemia, Gynecological infections, Bone and joints infections.
Bacterial infections in neutropenic patients. Full therapeutic doses of piperacillin and tazobactam for injection plus and amino glycoside should be used.
While piperacillin and tazobactam for injection is indicated only for the conditions previously listed, infections caused by piperacillin susceptible organism are also amenable to piperacillin and tazobactam for injection treatment due to its piperacillin content. Therefore, the treatment of mixed infections caused by piperacillin susceptible organisms and β-lactamase producing organism susceptible to piperacillin and tazobactam for injection should not require the addition of another antibiotic.
Appropriate culture and susceptibility test should be performed before treatment in order to identify organisms causing infections and to determine their susceptibilities to piperacillin and tazobactam for injection. Because of its broad-spectrum of activity against Gram-positive and Gram-negative aerobic and anaerobic organisms as previously listed, piperacillin and tazobactam for injection is particularly useful in the treatment of mixed infections and in presumptive therapy prior to the availability of the results of sensitivity test. Therapy with piperacillin and tazobactam for injection may, however be initiated before results of such test are known.
Modification of the treatment may be required once these results become available or if there is no clinical response.
In serious infections, presumptive therapy with piperacillin and tazobactam for injection may be initiated before susceptibility test results are available.
Piperacillin and tazobactam for injection acts synergistically with aminoglycosides against certain strains of Pseudomonas aeruginosa. Combined therapy has been successful, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. As soon as results of culture and susceptibility test become available, antimicrobial therapy should be adjusted.
Children under the age of 12 years: In hospitalized children aged to 2 to 12 years, piperacillin and tazobactam for injection is indicated for the treatment of serious intra-abdominal infections. It has not been evaluated in this indication for pediatric patients below the age or 2 years.